Stock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround

Stock Track03-30

REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.

The company reported a significant revenue increase of 89.55% year-on-year to RMB 3.242 billion and achieved a notable profit turnaround, with net profit attributable to owners reaching RMB 710 million compared to a loss of RMB 1.468 billion in the prior year. This performance was primarily fueled by strong sales growth of its key commercial products, Telitacicept for autoimmune diseases and Disitamab Vedotin for anti-tumor therapy.

Analysts from Huatai Securities highlighted REMEGEN's improving overseas potential and domestic business outlook. The pipeline is advancing steadily, with multiple Phase III trials expected to commence and key drug approvals anticipated in 2026. Additionally, revenue is projected to receive further support from upfront payments of licensing deals and the achievement of clinical milestones, particularly for RC148.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166072208?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 10:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166072208","market":"us","top_or_hot":-1,"title":"Stock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround","media":"Stock Track","content":"<p>REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.</p><p>The company reported a significant revenue increase of 89.55% year-on-year to RMB 3.242 billion and achieved a notable profit turnaround, with net profit attributable to owners reaching RMB 710 million compared to a loss of RMB 1.468 billion in the prior year. This performance was primarily fueled by strong sales growth of its key commercial products, Telitacicept for autoimmune diseases and Disitamab Vedotin for anti-tumor therapy.</p><p>Analysts from Huatai Securities highlighted REMEGEN's improving overseas potential and domestic business outlook. The pipeline is advancing steadily, with multiple Phase III trials expected to commence and key drug approvals anticipated in 2026. Additionally, revenue is projected to receive further support from upfront payments of licensing deals and the achievement of clinical milestones, particularly for RC148.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | REMEGEN Soars 10.04% Intraday on Strong Annual Results and Profit Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-30 10:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.</p><p>The company reported a significant revenue increase of 89.55% year-on-year to RMB 3.242 billion and achieved a notable profit turnaround, with net profit attributable to owners reaching RMB 710 million compared to a loss of RMB 1.468 billion in the prior year. This performance was primarily fueled by strong sales growth of its key commercial products, Telitacicept for autoimmune diseases and Disitamab Vedotin for anti-tumor therapy.</p><p>Analysts from Huatai Securities highlighted REMEGEN's improving overseas potential and domestic business outlook. The pipeline is advancing steadily, with multiple Phase III trials expected to commence and key drug approvals anticipated in 2026. Additionally, revenue is projected to receive further support from upfront payments of licensing deals and the achievement of clinical milestones, particularly for RC148.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1166072208","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166072208","pubTimestamp":1774836282,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.The company reported a significant revenue increase of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"个股赛道|REMEGEN盘中大涨10.04%业绩强劲扭亏为盈","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"REMEGEN's stock price soared 10.04% during intraday trading on Monday, driven by the company's release of robust 2025 annual financial results.The company reported a significant revenue increase of 89.55% year-on-year to RMB 3.242 billion and achieved a notable profit turnaround, with net profit attributable to owners reaching RMB 710 million compared to a loss of RMB 1.468 billion in the prior year. This performance was primarily fueled by strong sales growth of its key commercial products, Telitacicept for autoimmune diseases and Disitamab Vedotin for anti-tumor therapy.Analysts from Huatai Securities highlighted REMEGEN's improving overseas potential and domestic business outlook. The pipeline is advancing steadily, with multiple Phase III trials expected to commence and key drug approvals anticipated in 2026. Additionally, revenue is projected to receive further support from upfront payments of licensing deals and the achievement of clinical milestones, particularly for RC148.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166072208","isCrawlerRequest":true}